Connection

Carol Sherman to Humans

Back to Details
This is a "connection" page, showing publications Carol Sherman has written about Humans.
Carol Sherman
Connection Strength
0.104
Humans
  1. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol. 2006 Feb; 1(2):112-9.
    View in: PubMed
    Score: 0.010
  2. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep; 45(3):387-92.
    View in: PubMed
    Score: 0.009
  3. The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer. 2002 Jan; 38(2):279-91.
    View in: PubMed
    Score: 0.008
  4. Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol. 2000 Oct; 10(4):289-95.
    View in: PubMed
    Score: 0.007
  5. Limited small-cell lung cancer: a potentially curable disease. Oncology (Williston Park). 2000 Oct; 14(10):1395-403; discussion 1403-4, 1409.
    View in: PubMed
    Score: 0.007
  6. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.006
  7. Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31(4):238-42.
    View in: PubMed
    Score: 0.005
  8. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6.
    View in: PubMed
    Score: 0.005
  9. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7.
    View in: PubMed
    Score: 0.004
  10. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. 2011 Mar; 41(3):334-42.
    View in: PubMed
    Score: 0.004
  11. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
    View in: PubMed
    Score: 0.003
  12. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
    View in: PubMed
    Score: 0.003
  13. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. 2010 Jun; 28(5):340-8.
    View in: PubMed
    Score: 0.003
  14. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13.
    View in: PubMed
    Score: 0.003
  15. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
    View in: PubMed
    Score: 0.003
  16. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
    View in: PubMed
    Score: 0.003
  17. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer. 2004 Jun 15; 100(12):2671-9.
    View in: PubMed
    Score: 0.002
  18. Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42.
    View in: PubMed
    Score: 0.002
  19. Influence of celiac axis lymph nodes in the definitive treatment of esophageal cancer. Am J Clin Oncol. 2003 Jun; 26(3):215-20.
    View in: PubMed
    Score: 0.002
  20. The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease. Respir Care Clin N Am. 2003 Jun; 9(2):163-90.
    View in: PubMed
    Score: 0.002
  21. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
    View in: PubMed
    Score: 0.002
  22. Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36.
    View in: PubMed
    Score: 0.002
  23. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):19-24.
    View in: PubMed
    Score: 0.002
  24. Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):46-51.
    View in: PubMed
    Score: 0.002
  25. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):7-14.
    View in: PubMed
    Score: 0.002
  26. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2.
    View in: PubMed
    Score: 0.002
  27. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 1999 Jan; 115(1):242-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.